VIDEO: Similarities, differences between CAR T-cell therapies for multiple myeloma

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Currently with CAR T-cell therapies being utilized for late-relapse patients, we have two products — ide-cel and cilta-cel. Both of them are associated with a high response rate. I think there are differences in the duration of, or durability of response, but the side effects appear to be somewhat similar with both these products. The timing of those side effects may be a little bit different, but patients do get cytokine release syndrome. This is when you give CAR T-cell therapies, you know, these T cells are revved up and want to go after the BCMA as the target and release cytokines that can give flu-like or feverish symptoms — it mimics a bad infection in some ways. So, we manage those side effects in patients. Then patients can also have neurologic side effects that tend to happen early on in the course, but in the case of cilta-cel, they can happen as delayed effects sometimes with  Parkinsonian symptoms or nerve palsies — cranial nerve palsies as an example. And then very rarely do we have ongoing blood count recovery issues. There is, of course infection risk that one has to pay attention to as well. And  the patterns are a little different for different products, so for our physician colleagues listening to this, it would be a good idea to get in touch with your myeloma or transplant cellular therapy center of excellence and have more detailed discussions around some of these effects.